SEC Form 4 · accession 0001209191-17-045118
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glenn P Muir
Director
Period of report
Jul 11, 2017
Accepted (ET)
Jul 13, 2017 · 7:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $15.55 | Jul 11, 2017 | A | 20,000 | A | — | Jul 11, 2027 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1The stock option will vest in thirty-six monthly installments at the end of each successive month following July 11, 2017, subject to the Reporting Person's continued service as a director.